Nevertheless, HER2 positivity rate in ER+/PR− breast cancers ranges from 15 to 20% [14], indicating that a large amount of ER+/PR− tumors are HER2-negative and their etiology may not be explained by HER2 amplification. The gene discussed is ESR1; the disease is breast carcinoma.